PATENT CLAIM ANALYSIS

Application Number: 15763995
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-11
Patent Classification: ["514", "263100"]

Abstract:
Methods of treating a PD-1-resistant cancer are provided and comprise administering to a subject in need thereof a therapeutically effective amount of a c-Rel inhibitor and a therapeutically effective amount of a PD-1 inhibitor. A pharmaceutical combination comprising a therapeutically effective amount of a c-Rel inhibitor, and a therapeutically effective amount of a PD-1 inhibitor is also provided. Finally, methods of treating a cancer such as a CTLA-4-resistant cancer, a CD137-resistant cancer, and an OX-4-resistant cancer are provided and comprise administering to a subject in need thereof a therapeutically effective amount of a c-Rel inhibitor and a therapeutically effective amount of a CLTA-4, CD137 or OX-4 inhibitor, respectively.

Claim (Index 4):
The method of  claim 3 , wherein the pentoxifylline analog is selected from the group consisting of lisofylline, torbafylline, propentafylline, A81-138, IT-603, dyfylline, doxofylline, theophylline, isobutyl methylxanthine (IBMX), caffeine, and any combination thereof.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 90.0
- Lexical Diversity: 2.72093
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14918675', '15089579', '15303985', '14438310', '14755989']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6388649953121663
- 35 USC 102 Novelty (BERT): 0.5385180768170937
- Combined Prediction Score: 0.6288303034626591
- Mean Citation Score: 341.727634
- Max Citation Score: 351.19699999999995
- Similarity Product: 223.8239865518212

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test